Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
You can choose to fill it all the way or part way with water
Understanding the evidence, contraindications, and monitoring recommendations is essential for patients and clinicians considering this medication
Controlled human data on weight loss for this combination is limited, and neither peptide is approved for weight loss
Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
